In a phase @ study we aimed to assess the efficacy and safety of grazoprevir ( MK-@ ; HCV NS@/@A protease inhibitor ) and two doses of elbasvir ( MK-@ ; HCV NS@A inhibitor ) in patients with HCV mono-infection and HIV/HCV co-infection .